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In general terms, fetal growth restriction (FGR) is considered the impossibility of achieving the genetically determined potential size. In
the vast majority of cases, it is related to uteroplacental insufficiency. Although its origin remains unknown and causes are only known
in 30% of cases, it is believed to be related to an interaction of environmental and genetic factors with either a fetal or maternal origin.
One hypothesis is that alterations in the gastrointestinal microbiota composition, and thus alteration in the immune response, could
play a role in FGR development. We performed an observational, prospective study in a subpopulation affected with FGR to elucidate
the implications of this microbiota on the FGR condition.
A total of 63 fetuses with FGR diagnosed in the third trimester as defined by the Delphi consensus, and 63 fetuses with fetal growth
appropriate for gestational age will be recruited. Obstetric and nutritional information will be registered by means of specific
questionnaires. We will collect maternal fecal samples between 30 to 36 weeks, intrapartum samples (maternal feces, maternal and
cord blood) and postpartum samples (meconium and new-born feces at 6 weeks of life). Samples will be analyzed in the Department
of Biochemistry and Molecular Biology II, Nutrition and Food Technology Institute of the University of Granada (UGR), for the
determination of the gastrointestinal microbiota composition and its relationship with inflammatory biomarkers.
This study will contribute to a better understanding of the influence of gastrointestinal microbiota and related inflammatory
biomarkers in the development of FGR.
Trial registration: NCT04047966. Registered August 7, 2019, during the recruitment stage. Retrospectively registered. Ongoing
research.
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Abbreviations: AGA = appropriate for gestational age, CPR = cerebroplacental ratio, EFW = estimated fetal weight, ELISA =
enzyme-linked immunosorbent assay, FGR = fetal growth restriction, IFN-g = interferon-g, IL = Interleukin, IUGR = Intrauterine
growth restriction, LBP = LPS-binding protein, LPS = lipopolysaccharide, PCR = polymerase chain reaction, rRNA = ribosomal
RNA, SGA= small for gestational age, TLR4= toll-like receptor 4, TNF-a= tumor necrosis factor-alpha, UtA= uterine artery, VEGF=
vascular endothelial growth factor.
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1. Introduction
Fetal growth restriction (FGR) is usually defined as a failure to
achieve fetal growth potential and affects up to 6% to 10% of all
new-born.[1–3] FGR is associated with poor perinatal and long-
term postnatal outcomes, such as worse long-term neurological,
cardiovascular, and endocrinological development.[4–5]
The current FGR classification differentiates between early-
and late-onset FGR. Early-onset cases are the most severe forms
with worse outcomes, but late-onset FGR represents 70% to
80% of the FGR, and it is also associated with suboptimal
neurological and cardiovascular outcomes. This classification
helps in the understanding of the different presentations of the
disease, and the cut-off to define each phenotype has commonly
been set at approximately 32 to 34 weeks at diagnosis. In
addition, a new classification within FGR differentiates 2
populations, that is, intrauterine-growth-restriction (IUGR)
and small-for-gestational-age (SGA), according to the presence
of several criteria such as growth below the 3rd percentile or
abnormal uterine artery Doppler (UtA) or cerebroplacental ratio
(CPR). This classification has been demonstrated to be very useful
for identifying small fetuses with worse perinatal outcomes and
short-term cardiovascular outcomes.[6]
Maternal, genetic, and environmental factors such as smoking,
hypertension, severe chronic anemia, pregestational diabetes
mellitus, autoimmune diseases, genetic alterations, congenital
infections or malformations increase the risk of developing FGR,
and those risk factors explain 30% of the cases.[7] It is postulated
that placental dysfunction may play an important role in this
subpopulation.[8] Studies performed in animals and humans have
suggested that the microbial colonization process is crucial for
immunological and physiological development.[9] The human
microbiome is defined as the set of microorganisms that inhabit
each part of the body. Until recently, it was accepted that the
uterus was a sterile environment, but this concept has changed
due to new sequencing techniques that suggest that the fetus, the
placenta, and the amniotic fluid are not sterile and that the
acquisition and colonization of the gastrointestinal tract begin in
the uterus.[10] This fact could also be explained by the meconium,
which is the first intestinal discharge of the new-born. In the
recent literature, it has been shown to have similar types of
microorganisms as those of the amniotic fluid and placenta,
reflecting the uterus.[11] Furthermore, the neonatal microbiota is
affected by the mode of delivery; however, recent results
suggested that within the first 6 weeks of life, the infant
microbiota undergoes substantial reorganization that is mainly
driven by body site.[11] The alteration of the gastrointestinal
microbiota, also called dysbiosis, has been related to a number of
diseases, namely, obesity, metabolic syndrome, diabetes, and
maternal-fetal conditions.[12,13] The composition of the intestinal
microbiota during pregnancy undergoes profound changes, some
of which are similar to those observed in obesity.[14] For example,
it has been described that there is an increase in the number of
intestinal bacteria that potentially metabolize amino acids at the
end of pregnancy, which is more abundant in pregnant women
who are overweight than in those with normal weight.[14] Other
studies indicate that changes in the intestinal microbiota may
contribute to the development of pre-eclampsia,[15] and the
alteration of the gastrointestinal and vaginal microbiota has been
related to an increased risk of preterm birth.[16] Despite the
current interest in this issue, there are no concrete data on the
relationship betweenmaternal and fetal intestinal microbiota and
FGR.
It is well known that the gastrointestinal microbiota is an
essential mediator of metabolism and the immune system. There
is strong evidence that complications during pregnancy, includ-
ing FGR, are associated with aberrant maternal inflammation.[17]
Similarly, it has been demonstrated in animal models that
activation of Toll-like receptor 4 (TLR4) induces premature birth
and FGR.[18] In addition, an alteration in the composition of the
intestinal microbiota results in high levels of lipopolysaccharide
(LPS), which is a component of the Gram-negative bacterial wall
and the main ligand of TLR4. The junction of LPS-TLR4
produces a metabolic endotoxemia capable of modulating pro-
inflammatory cytokines. In fact, women affected by FGR/pre-
eclampsia have a high inflammatory status characterized by an
increase in cytokines and chemokines such as tumor necrosis
factor alpha (TNF-a) and interleukin (IL) 6, both systemically
and in the placenta.[19] Furthermore, it has been demonstrated in
animals that maternal exposure to LPS at the end of pregnancy
leads to FGR development.[20]
According to what has been previously stated, it seems that
there is a relationship between the intestinal microbiota and the
development of FGR. However, more clinical studies are needed
to support this hypothesis. The present study proposes the
realization of an observational clinical study in a population with
late-onset FGR (pregnant women and new-born), compared to
non FGR population (pregnant women and new-borns with fetal
growth appropriate for gestational age [AGA]).
The main aim of the study is to identify the modification in the
intestinal microbiota in pregnant women and new-borns with
pregnancies with FGR in comparison with AGA. Secondary aims
are to determine differences in the blood inflammatory
biomarkers between pregnant women and new-borns with
FGR and AGA controls. We will also assess whether changes
in inflammatory parameters are associated whit modification of
the intestinal microbiota. Finally, we will also studies the
intestinal microbiota of the neonates and controls at 6 weeks of




This study is an observational, prospective study. The trial will be
conducted by members of both BCNatal (Barcelona Center of
Maternal-Fetal and Neonatal Medicine), Hospital Sant Joan de
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Déu, University of Barcelona as well as the Institute of Food
Nutrition and Technology “José Mataix”, Department of
Biochemistry and Molecular Biology II of the University of
Granada. Participants will include 63 pregnant women with fetal
growth appropriate for gestational age (AGA) and 63 women
affected by FGR, recruited during the third trimester of
pregnancy (30–36 weeks). At BCNatal, cases will be recruited
as all of the consecutive small fetuses diagnosed during the period
of the study, and controls will be randomly selected from low-risk
pregnancies. Pregnant women will answer some questionnaires
about obstetric, nutritional, demographic, epidemiological, and
clinical variables. Maternal samples (feces) will be harvested
between 30 to 36 weeks as well as intrapartum samples (feces,
maternal, and cord blood) and postpartum samples (meconium
and feces of new-borns at 6 weeks of age). In Table 1, we depict
the specimen collection schedule. The data and samples will be
codified according to the BCNatal – Hospital Sant Joan de Déu
biobank and sent to the biobank of the Public Health System of
Andalusia (BBSPA). The samples will be sent, managed and
processed in accordance with the BBSPA guidelines. All analyses
will be performed in the Department of Biochemistry and
Molecular Biology II of the University of Granada.
The BIOCIR protocol (BIOCIR version 1) has been approved
by the local Ethics Committee of Hospital Sant Joan de Déu and
Granada with references PIC-40–18 and 02032018, respectively,
and will be conducted according to the standards given in the
Declaration of Helsinki and Good Clinical Practice Guidelines.
Data will be protected from uses not allowed by people outside
the investigation, and their confidentiality will be respected in
accordance with Organic Law 3/2018, of December 5, on the
Protection of Personal Data and Digital Rights and Law 41/2002,
of November 14, basic law regulating patient autonomy and
rights and obligations regarding information and clinical
documentation. All investigators participating in the study are
appropriately qualified.
2.2. Study population and eligibility criteria
The study population will comprise 126 singleton pregnancies
recruited during the third trimester of gestation (30–36 weeks). It
will include 63 AGA (fetuses with estimated fetal weight (EFW)
>10th percentile) and 63 fetuses with FGR (EFW <10th
percentile), according to the Delphi criteria.[21] In all pregnancies,
gestational age will be calculated based on crown-rump length at
the first-trimester ultrasound,[22] and estimated fetal and birth
weight centiles will be calculated adjusted for the gestational age
at delivery and neonatal sex using local reference curves.[23] At
the recruitment time, the exclusion criteria will be the following:
drug consumption, including tobacco, alcohol ingestion, use of
any antibiotics during the 3 months prior to recruitment,
premature rupture of membranes, gestational diabetes, and fetus
malformation. Furthermore, all pregnant women with delivery
before 37 weeks will be excluded. The first patient was recruited
on July, 2018 and the estimated recruitment competition date has
been extended until December 31, 2020.
The STrengthening the Reporting of Observational studies in
Epidemiology (STROBE) Statement guidelines for this observa-
tional study and the Standard Protocol Items: Recommendations
for interventional trial has been follow-up (Additional file 1,
http://links.lww.com/MD/F17).
2.3. Sample size
The sample size was estimated based on the primary outcome:
intestinal microbiota composition. Based on the results of
previous studies,[15] the number of subjects that need to be
included in the study to detect differences among the studied
cohorts, assuming an alpha error of 5% and a beta error of 20%,
is 53 pregnant women per branch. Assuming an acceptance rate
of 80%, we need to include a total of 63 pregnant women in each
branch in the initial sample.
2.4. Outcome measures
2.4.1. Intestinal microbiota composition. The determination
of the intestinal microbiota composition will be carried out from
16S rRNA analysis. DNA will be obtained using the QIAamp
DNA stool mini kit (Qiagen, Barcelona, Spain) and the PureLink
Microbiome DNA purification kit (Invitrogen) from maternal
and neonatal fecal samples, and the quality and quantity will be
tested spectrophotometrically using a NanoDrop ND-100
spectrophotometer. The variable region V3-V4 of the 16S rRNA
gene will be PCR-amplified using specific oligonucleotides.[24]
Subsequently, a second amplification will be performed using
barcode oligonucleotides. Individual “barcode” sequences are
added to each DNA fragment during next-generation library so
that each read can be identified and sorted before the final data
analysis. These barcodes, or index adapters, are unique identifiers
on both ends of the sample. It involves 96 unique Index 1 (i7)
Table 1
Maternal and infant specimen collection schedule.
t0 t1 t3 t4
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H = hour, t = time.
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adapters and 96 unique Index 2 (i5) adapters, preventing
repeated sequences in a well plate (Illumina, Inc). The purified
PCR product will be sequenced on an Illumina MiSeq platform,
which is located in the Microbiology Service of the San Cecilio
University Hospital in Granada, Spain. Estimated completion
data on May 2021.
2.4.2. Inflammatory biomarkers. The study of inflammatory
biomarkers will be performed in plasma samples from maternal
(t0 and t1) and umbilical cord blood (t1). The concentrations of
LPS and LBP will be determined by simple ELISA using LS-
F17912 and LS-F21929 kits (LSbio), respectively. Simultaneous
detection of inflammatory biomarkers will be performed using
MILLIPLEXMAP test kits (Millipore Corp, Billerica, MA) and
Luminex xMAP detection technology. The HSTCMAG-28SK kit
will be used for the determination of IL-6, IL-8, IL-10, IL-23 and
IFN-g and HCYTOMAG-60K for VEGF and IL-15. Estimated
completion data on April 2021.
2.5. Statistical analysis
Data analysis will be performed at the end of the observational
study. The normality of variables will be assessed. Variables not
following a normal distribution will be log transformed. Normal
variables will be expressed as the mean and standard error of the
mean (SEM). In order to determine differences between the case-
control group a Students t test for independent samples will be
carried out. In addition, a one-way ANOVA will be also
performed. If the measured variables are not distributed in a
normal way, the analysis of the data will be performed by non-
parametric tests of comparison of distributions. The Mann–
Whitney U test will be used for the case of 2 groups. Linear
regression models, Principal Components Analysis (PCA) and
Pearson Correlations will be used to determine associations of the
intestinal microbiota composition with inflammatory biomarkers
and clinical parameters. A statistical significance of 0.05 will be
established for the contrasts of hypotheses for the population
inference. Statistical analyses will be performed using R 3.0 and
SPSS v20.0 (IBM, Chicago, IL) programs.
For the analysis of the sequences obtained by parallel massive
sequencing, a pre-processing of the sequence analysis based on
theMG-RAST server will first be performed.Mothur will be used
for denoising, elimination of redundancy and thus making a
correct alignment for developing distance matrices, clusters and
OTUs (operational taxonomic units). We will calculate the intra-
sample diversity (diversity-a) with the obtained OTUs. We will
use the Greengenes database to taxonomically classify all
sequences. The b diversity will be calculated and thus generate
3D principal coordinate analysis (PCoA) diagrams for represent-
ing the differences between the various samples. For the detection
of differences taking into account the abundance between groups,
we will use “Metastats”.
3. Discussion
Our study is a case-control clinical trial that aims to determine the
gastrointestinal composition and related inflammatory biomark-
ers in FGR. Previous studies have described an association
between the gastrointestinal microbiota and different maternal-
fetal conditions. In this regard, supplementation with specific
probiotic strains, namely, Lactobacillus rhamnosus GG and
Lactobacillus acidophilus, together with dietary recommenda-
tions, has been found to improve glucose metabolism in pregnant
and lactating women.[25] In rats, it has been described that FGR
induces changes in the intestinal microbiota composition, and
those changes persisted throughout life.[26] However, there is
very little knowledge about the interplay between gastrointestinal
microbiota, inflammatory biomarkers and FGR in humans.
Additionally, in healthy pregnant women has been shown that
maternal microbiota can be clustered in 2 distinct microbial
groups predominantly charazed by a higher abundance of
Prevotella (Cluster I) and a higher abundance of the Romino-
coccus Kspecies (Cluster II). This cluster were associated to a diet
rich in carbohydrate (Cluster I) or with higher intakes of
vegetables proteins and fats (Cluster II).[27]
To the best of our knowledge, this is the first study registered
on ClinicalTrials.gov with the aim of studying the relationship
between the FGR condition and microbiota. Fetal growth is a
complex process affected by different factors coming from the
mother and/or the fetus. We hypothesize that both the
gastrointestinal microbiota and the related inflammatory pro-
cesses have an important role in the development of FGR. This
study will also allow us to understand the underlyingmechanisms
in this relationship.
There are limitations to this study. First, we are aware that
microbiota can be affected by different factors (genetic, stress,
diet, physical activity, and delivery mode, among others), and for
this reason, we will also collect lifestyle questionnaires. Besides, 1
important issue is the homogeneity of the patients, for that we
established a stringent set of inclusion and exclusion criteria in an
attempt to control this factor.
All things considered, the obtained results will help to better
understand the FGR pathophysiology and the related mecha-
nisms, and the results of this study could be translated into new
clinical recommendations to improve both maternal and fetal
health.
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